Intensity Therapeutics (INTS) Expected to Announce Quarterly Earnings on Tuesday

Intensity Therapeutics (NASDAQ:INTS) is expected to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($1.0850) per share for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings results on Friday, March 27th. The company reported ($0.31) earnings per share (EPS) for the quarter. On average, analysts expect Intensity Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Intensity Therapeutics Trading Up 1.0%

INTS traded up $0.05 on Tuesday, hitting $5.25. 6,244 shares of the company were exchanged, compared to its average volume of 46,423. The firm has a fifty day simple moving average of $6.17 and a two-hundred day simple moving average of $8.74. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.92 and a current ratio of 5.92. Intensity Therapeutics has a 12 month low of $4.63 and a 12 month high of $43.50. The stock has a market capitalization of $13.91 million, a PE ratio of -0.33 and a beta of 2.94.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of Intensity Therapeutics by 77.8% in the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after acquiring an additional 201,357 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Intensity Therapeutics in the 4th quarter worth approximately $26,000. State Street Corp raised its position in shares of Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in shares of Intensity Therapeutics in the 4th quarter worth approximately $41,000. Institutional investors own 3.74% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wall Street Zen upgraded Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Freedom Capital upgraded Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th. Finally, Weiss Ratings cut Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Intensity Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.